Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have been assigned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $16.88.

Several analysts have weighed in on FOLD shares. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Monday, January 13th. JPMorgan Chase & Co. upped their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Finally, Bank of America boosted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th.

Amicus Therapeutics Stock Performance

FOLD stock opened at $9.41 on Wednesday. The stock has a market capitalization of $2.81 billion, a PE ratio of -27.68, a price-to-earnings-growth ratio of 1.25 and a beta of 0.62. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. The company has a 50 day moving average price of $9.70 and a 200 day moving average price of $10.53. Amicus Therapeutics has a fifty-two week low of $8.78 and a fifty-two week high of $14.03.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,901 shares of Amicus Therapeutics stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $11,083,175. This trade represents a 0.88 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 22,901 shares of company stock worth $259,863 in the last quarter. Corporate insiders own 2.20% of the company’s stock.

Institutional Trading of Amicus Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP boosted its holdings in shares of Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after buying an additional 2,856,101 shares during the period. Millennium Management LLC raised its position in shares of Amicus Therapeutics by 1,758.9% in the second quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company’s stock valued at $18,790,000 after buying an additional 1,792,277 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Amicus Therapeutics in the third quarter worth $13,530,000. Assenagon Asset Management S.A. increased its stake in Amicus Therapeutics by 141.1% in the third quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company’s stock valued at $21,765,000 after acquiring an additional 1,192,489 shares during the last quarter. Finally, Squarepoint Ops LLC boosted its stake in Amicus Therapeutics by 159.1% in the second quarter. Squarepoint Ops LLC now owns 650,555 shares of the biopharmaceutical company’s stock valued at $6,454,000 after buying an additional 399,449 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.